Header: Pillar releases a circa 22-gene kit of the popular tumor oncogenes as RUO. MSK validates it as "MSK React."
##
I was a bit confused by the title of a current Genomeweb article -
Cancer Centers Look to New NGS-Based 'Frankenpanel' to Get Fast Info on Clinically Actionable Genes
(Subscription, here.)
I wasn't sure what a Frankenpanel was. But I quickly linked this (see also a public press release on August 27 by Pillar) to the idea of running a few key oncogenes really fast, up front, while you are waiting for a 500-oncogene NGS CGP panel.
From the press release, Pillar launches "oncoReveal Nexus" as an RUO kit, while Memorial Sloan-Kettering has validated it - including NYS validation - as the brand name, "MSK REACT."
CAP Today remarked it will generally run on a MiSeq.
I was also reminded of work by Dagogo-Jack and colleagues at MGH on carefully planning the whole story-arc of coordinated interdepartmental molecular oncology, including positioning of a few tests upfront, like EGFR in lung cancer (Dagogo-Jack et al., 2023).
Genomeweb includes a comment that reimbursement is undefined yet. MSK has a 500-gene 510(k) cleared test called MSK IMPACT which could complement REACT but on a slower timetable.
##
Google offers a historical use of "frankenpanel" in the context of arcade games that are too complicated (like a 747's panel, 2013).
See a new paper by Agarwal et al., supported by PMC, on the value and impact of integrated approaches to personalized medicine in health systems.
